The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG).
期刊：DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System [Royal Netherlands Academy of Arts and Sciences] 日期：2001-11-16被引量：1
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
Criminology34
Kao
OK
小小牛马
有人
cdercder
张欢馨
GingerF
炜大的我
东方元语
Essence
科科
乐空思
ming2026
sanvva
lucky
luang
一介书生
赵赶超
皖公网安备34019202002308
